Article

Lipidomic Profiling of Ipsilateral Brain and Plasma after Celastrol Post-Treatment in Transient Middle Cerebral Artery Occlusion Mice Model

Maozhu Liu †, Mengyuan Chen †, Ying Luo, Hong Wang, Haifeng Huang, Zhe Peng, Miaomiao Li, Huizhi Fei, Wen Luo and Junqing Yang *

Chongqing Key Laboratory of Biochemistry and Molecular Pharmacology, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; maozhu2021@126.com (M.L. Maozhu Liu); cmy116165@126.com (M.C.); 100894@cqmu.edu.cn (Y.L.); 101832@cqmu.edu.cn (H.W.); huanghf31@163.com (H.H.); pengzsunshine163.com (Z.P.); 15320497853@163.com (M.L. Miaomiao Li); feihuizhi198863@163.com (H.F.); qq.xiao.wen@163.com (W.L.)

* Correspondence: cqyangjq@cqmu.edu.cn; Tel.: +86-136-3780-9247

† These authors have contributed equally to this work.

Abstract: Celastrol, a pentacyclic triterpene isolated from the traditional Chinese medicine Tripterygium wilfordii Hook. F., exhibits effectiveness in protection against multiple central nervous system (CNS) diseases such as cerebral ischemia, but its influence on lipidomics still remains unclear. Therefore, in the present study, the efficacy and potential mechanism of celastrol against cerebral ischemia/reperfusion (I/R) injury were investigated based on lipidomics. Middle cerebral artery occlusion (MCAO) followed by reperfusion was operated in mice to set up a cerebral I/R model. TTC staining and TUNEL staining were used to evaluate the therapeutic effect of celastrol. Ultra-performance liquid chromatography-tandem mass spectrometry (UPLC/MS) was employed for lipidomics analysis in ipsilateral hemisphere and plasma. Celastrol remarkably reduced cerebral infarct volume and apoptosis positive cells in tMCAO mice. Furthermore, lipidomics analysis showed that 14 common differentially expressed lipids (DELs) were identified in brain and five common DELs were identified in plasma between the Sham, tMCAO and Celastrol-treated tMCAO groups. Through enrichment analysis, sphingolipid metabolism and glycerophospholipid metabolism were demonstrated to be significantly enriched in all the comparison groups. Among the DELs, celastrol could reverse cerebral I/R injury-induced alteration of phosphatidylcholine, phosphatidylethanolamine and sulfatide, which may be responsible for the neuroprotective effect of celastrol. Our findings suggested the neuroprotection of celastrol on cerebral I/R injury may be partially associated with its regulation of lipid metabolism.

Keywords: cerebral ischemia/reperfusion injury; celastrol; lipidomics; neuroprotection; UPLC/MS

1. Introduction

Stroke is a serious disease with high mortality and disability rates worldwide. In China, stroke is the leading cause of death and its prevalence and incidence are increasing [1]. The risk of stroke increases with age, but can occur at any age. Risk factors, such as tobacco and work-related productivity, can contribute to stroke in young people [2,3]. Therefore, it is worthwhile to study stroke in young age. Of all strokes, approximately 70 to 80% of cases are ischemic stroke characterized by cerebrovascular occlusion and blood supply insufficiency, and the remaining strokes caused by cerebrovascular rupture are hemorrhagic stroke [4]. For ischemic stroke, rapid restoration of blood flow to the brain with intravenous thrombolysis or endovascular thrombectomy can help reduce the ischemic brain injury. However, the paradox is that the blood recovery may exacerbate brain damage due to various reasons, which is called cerebral ischemia/reperfusion (I/R) injury [5]. At present, drugs used to reduce cerebral I/R injury are very limited in clinical settings. Hence, there is
an urgent need to develop highly effective and low toxic therapeutic drugs for the treatment of cerebral I/R injury.

Traditional Chinese medicines (TCMs) have been used for the treatment of cerebrovascular diseases such as stroke for more than two thousand years [6]. Currently, based on the neuroprotective effects of TCMs, the development of new effective TCMs for stroke treatment has increasingly been attracting attention. Celastrol (3-Hydroxy-24-nor-2-oxo-1(10), 3,5,7-friedelatetraen-29-oic acid), a pentacyclic triterpene isolated from the traditional Chinese medicine Tripterygium wilfordii Hook. F., with various pharmacological activities including anti-inflammatory [7–9], anti-oxidative effects [10–12], and more importantly, modulating lipid metabolism [13,14]. In recent years, the effect of celastrol on the CNS has received much attention. Increasing studies found that celastrol is an effective neuroprotective agent against cerebral ischemic injury. A previous study has illustrated that celastrol improved ischemic brain damage in a rat permanent middle cerebral artery occlusion (pMCAO) model via downregulating p-JNK, p-c-Jun and NF-κB [15]. More recently, celastrol has been reported to ameliorate ischemic stroke-induced brain injury by promoting IL-33/ST2-mediated M2 microglial polarization [16]. Another study also demonstrated that celastrol could attenuate neuroinflammation, decrease neuronal apoptosis and oxidative stress through inhibiting HMGB1/NF-κB signaling pathway, thereby alleviating cerebral I/R injury in rats [17]. These results indicated that celastrol may become a promising therapeutic drug for the treatment of ischemic stroke. However, the protective effect and molecular mechanism of celastrol in cerebral I/R injury still need further investigation.

The brain is a highly lipid-dense organ and lipid homeostasis is necessary for maintaining the normal structure and function of the CNS. The changes in lipid metabolism after stroke may aggravate or reduce brain damage, thus affecting the prognosis of stroke. Lipidomics is a high-throughput analytical technology based on liquid chromatography-tandem mass spectrometry (LC-MS/MS), which is a key approach to further understand the pathogenesis of ischemic stroke, and can be used to screen lipid biomarkers with clinical diagnosis, treatment, and prognostic value in various biological samples (serum, plasma, urine, tissues, etc.) [18,19]. Moreover, lipidomics can also help to explore the potential mechanism of drug therapy in ischemic stroke [13,19]. For example, serum levels of high-density lipoprotein cholesterol (HDL-C) were contributed to early neurological deterioration in patients with ischemic stroke [20]. Other research reported that lower serum triglyceride (TG) and HDL-C levels were responsible for the increase in stroke severity [21]. Lipids such as lysophosphatidylcholines (LPCs), phosphatidylcholines (PCs), sphingomyelins (SMs), phosphatidylethanolamines (PEs) and ceramides (CMs) in ischemic brain tissues were reported to be involved in the pathogenesis of ischemic stroke [19,22,23]. Furthermore, regulation of lipid levels and lipid-related metabolic pathways including glycerophospholipid metabolism, arachidonic acid metabolism and sphingolipid metabolism is also an important mechanism for the neuroprotective effects of stroke treatment drugs [24–27]. These investigations indicated that metabolites of lipid metabolism may play a critical role in cerebral I/R injury rather than merely act as biomarkers. Recently, celastrol has been proved to reverse lipid metabolism disorders in different diseases. Lipidomic analysis showed that celastrol restored the levels of PCs, LPCs, SMs and CMs in 3T3-L1 adipocytes and hyperlipidemia mouse serum by regulating lipid synthesis and metabolism associated genes [13]. Study of experimental colitis found that celastrol played an anti-inflammatory effect by intervening LPC and SM metabolism in serum and colon of colitis mice [14]. However, celastrol on lipid metabolism in the brain of cerebral I/R injury and the relationship between the metabolites of lipid metabolism and neuroprotection remains largely unknown.

Therefore, in this context, we examined the neuroprotection of celastrol in transient middle cerebral artery occlusion (tMCAO) mice model via TTC staining and TUNEL test. Additionally, we then applied lipidomics investigations based on UPLC/MS to evaluate the different lipid metabolites in the ipsilateral hemisphere and plasma in tMCAO mice model, especially the differences between the celastrol treated or not after the onset of
reperfusion. Furthermore, we screened the lipid metabolites via bioinformatics and found that sphingolipid and glycerophospholipid metabolic pathways may play an important role during the cerebral I/R injury, which may still need further investigation to mine the underlying mechanism.

2. Results

2.1. Cerebral Infarction Evaluation and TUNEL Staining

The tMCAO mice model was successfully built, the mean CBF of MCA was decreased 80%. After 1 h occlusion, the suture was removed to allow the reperfusion. The mean CBF of MCA was increased to 70%. At 24 h after reperfusion, the ischemic hemisphere brain samples and blood samples were collected for further tests (Figure 1A). TTC staining was used to distinguish infarcted brain tissues to assess the severity of brain damage, as shown in results, no cerebral infarct lesion was observed in Sham group, whereas the infarct volume was apparently increased in tMCAO mice (32.7 ± 5.1%) (Figure 1B,C, p < 0.0001 vs. Sham group). Treatment with 4.5 mg/kg celastrol significantly reduced I/R-induced infarct volume to 18.7 ± 3.9% (Figure 1B,C, p < 0.001 vs. tMCAO group). TUNEL staining was used to examine the anti-apoptotic effects of celastrol. More apoptotic cells were observed in tMCAO group than that of Sham group. While compared with tMCAO group, the apoptotic cells in the cortex and hippocampus CA1 regions were decreased in Celastrol-treated tMCAO group (Figure 1D). These findings suggested that celastrol possessed significant neuroprotective properties against cerebral I/R injury in experimental animals.

Figure 1. Celastrol effectively protected against cerebral ischemia reperfusion injury in mice. (A) Flow chart of experimental protocol. (B) Representative TTC staining images at 24 h after reperfusion. The ischemic portion appeared white and the non-ischemic portion appeared red. (C) Quantitative analysis of infarct volume (n = 5–6). (D) Results of TUNEL staining in the ipsilateral cerebral cortex and hippocampal CA1 regions (magnification: 400×, scale bar = 50 µm). Data were presented as mean ± SEM. ***p < 0.001, ****p < 0.0001.
2.2. Multivariate Data Analysis for Plasma and Brain Samples

Metabolomics profiling of the plasma and brain samples was carried out by using UPLC/MS. PLS-DA was used to further investigate the degree of similarities and differences between the Sham, tMCAO and Cela-treated tMCAO groups. The results identified a clear separation of the three groups in plasma (Figure 2A,B) and brain (Figure 2C,D). We can clearly see two principal components including PC1 (16.17%) and PC2 (26.30%) of plasma (Figure 2A) and two separate components including PC1 (16.52%) and PC2 (10.81%) of brain (Figure 2C). Similarly, the plasma of Cela-treated and untreated tMCAO mice was also significantly divided into PC1 (15.04%) and PC2 (29.76%) (Figure 2B). Meanwhile, the brain of Cela-treated and untreated tMCAO mice were always separated clearly (Figure 2D). These may indicate a broad role of celastrol in treating tMCAO mice.

Figure 2. Non-targeted lipidomics analysis of brain and plasma after tMCAO and Cela-treated tMCAO from mice. Plot of brain and plasma PLS-DA between Sham and tMCAO (A,C) groups, tMCAO and Cela-treated tMCAO (B,D) groups.

2.3. Differentially Expressed Lipids (DELs) Identification

The fold change (FC) > 2, p < 0.05 and VIP value > 1 were used as the threshold to identify the DELs between two groups. A total of 128 DELs (100 upregulated and 28 downregulated) were found between tMCAO and Sham groups in plasma (Table S1), while there were 54 DELs (14 increased and 40 decreased) after tMCAO mice treated by celastrol in plasma (Table S2). The volcano plots (Figure 3A,B) and heatmap (Figure 4A,B) showed the expression level of DELs between Sham, tMCAO and Celastrol-treated tMCAO
In order to evaluate the key lipids which induced by stroke and celastrol treatment, we used a venn map to find the common lipids between tMCAO mice and Celastrol-treated tMCAO mice in plasma and brain. In the ischemic hemisphere, the analysis showed that there were 14 common DELs between brain_tMCAO/Sham and brain_Cela/tMCAO groups (Figure 5, Red Arrow). Compared with Sham group, the levels of 13 lipid metabolites (i. 2-hydroxybutyric acid, ii. PS (dime(11,3)/dime(11,5)), iii. PI (40:5), iv. 1,2-di-(9z,12z, 15z-octadecatrienyl)-3-(galactosyl-alpha-1-6-galactosyl-beta-1)-glycerol, v. 4-phenylpyridine, vi. (1alpha,2beta,3alpha,11alpha)-1a,2,3,11c-tetrahydro-6,11-dimethylbenzo[6,7]phenanthro oxirene-2,3-diol, vii. erucic acid, viii. CE (20:5), ix. ceramide (d18:1/25:0), x. jubanine c, xi. TG (36:4), xii. PS (dime(11,3)/dime(13,5)), xiii. 3-o-sulfogalactosylceramide (d42:2) were increased in tMCAO group, and only one lipid metabolite (l-aspartyl-4-phosphate) were decreased in tMCAO group. The changes in all of the 14 DELs were reversed when treated by celastrol. Meanwhile, in the plasma, the analysis only exhibited five common DELs between plasma_tMCAO/Sham and plasma_Cela/tMCAO groups. Compared with Sham group, the 4 lipid metabolites (i. PS (42:8), ii. PE (42:7), iii. all trans decaprenyl diphosphate, iv. 3-o-sulfogalactosylceramide) were significantly increased in tMCAO group, and also only one lipid metabolite (PC (44:10) was decreased in MCAO group (Figure 5, Blue Arrow). All of the five DELs were found to exhibit a normal-level tendency in Celastrol-treated tMCAO mice. Unexpectedly, we did not find common DELs not only between
plasma_Cela/tMCAO and brain_Cela/tMCAO groups (Figure 5, Red Circle), but also between plasma_tMCAO/Sham and brain_tMCAO/Sham groups (Figure 5, Blue Circle). These results indicated that the lipid metabolism in the ischemic hemisphere and plasma of cerebral I/R injury, no matter treated by celastrol or not, may share several common metabolic pathways, but the specific metabolic process/pattern may different.

The volcano plots (Figure 3C,D) and heatmap (Figure 4C,D) also showed the expression level of DELs between Sham, tMCAO and Celastrol-treated tMCAO groups in ischemic hemisphere. From the results above, significant differences of endogenous lipid metabolites between Sham, tMCAO and Celastrol-treated tMCAO mice were identified. Therefore, celastrol may play a role in the treatment of tMCAO mice by altering the expression of certain lipid metabolites.

Figure 3. The volcano map showed the differential lipids expression level among the Sham mice, tMCAO mice and Celastrol-treated tMCAO mice. The red color indicates the upregulated lipids, while green color represents the downregulated lipids. (A) plasma_tMCAO/Sham, (B) plasma_Cela/tMCAO, (C) brain_tMCAO/Sham and (D) brain_Cela/tMCAO groups.

Figure 4. Heatmap of the expression of differential lipids in different comparison groups. (A) plasma_tMCAO/Sham, (B) plasma_Cela/tMCAO, (C) brain_tMCAO/Sham and (D) brain_Cela/tMCAO groups.

2.4. Pathway Analysis and Possible Underlying Pathways

In order to further explore the effect of celastrol on metabolic pathways in tMCAO mice, the significantly changed lipids were subjected to MetaboAnalyst software and the enriched KEGG pathway between the Sham, tMCAO and Celastrol-treated tMCAO groups were exhibited by bubble plots (Figure 6, Tables 1–4, Tables S5 and S6). There are nine and seven enriched pathways in plasma_tMCAO/Sham and plasma_Cela/tMCAO groups, respectively (Figure 6A,B). Additionally, six common pathways (i. glycerophospholipid metabolism, ii. linoleic acid metabolism, iii. alpha-linolenic acid metabolism, iv. glycosylphosphatidylinositol (GPI)-anchor biosynthesis, v. sphingolipid metabolism, vi. arachidonic acid metabolism) were found between plasma_tMCAO/Sham and plasma_Cela/tMCAO groups. Meanwhile, there are 14 and 7 enriched pathways in brain_tMCAO/Sham and brain_Cela/tMCAO groups, respectively (Figure 6C,D). A total of seven common pathways (i. sphingolipid metabolism, ii. propionate metabolism, iii. alanine, aspartate and glutamate metabolism, iv. glycerophospholipid metabolism, v. steroid biosynthesis, vi. metabolism of xenobiotics by cytochrome P450, vii. steroid hormone biosynthesis) were enriched between brain_tMCAO/Sham and brain_Cela/tMCAO groups. Among the above enriched pathways, we found that sphingolipid metabolism and glycerophospholipid metabolism were not only significantly enriched (Tables 1–4, p < 0.05) in most comparison groups, but also significantly enriched (p < 0.05) in brain and plasma no matter celastrol treatment or not. Furthermore, three top frequency metabolites including phosphatidylcholine, phosphatidylethanolamine and sulfatide, which belong to glycerophospholipid metabolism and sphingolipid metabolism as well (Table S7), may closely related to the
potential mechanism of lipid metabolism as well as the neuroprotective effect of celastrol in cerebral I/R injury.

Figure 5. The common and unique differential lipids of different comparison groups.

Figure 6. Summary of KEGG pathway analysis with MetaboAnalyst. (A) plasma_tMCAO/Sham, (B) plasma_Cela/tMCAO, (C) brain_tMCAO/Sham and (D) brain_Cela/tMCAO.
### Table 1. The enriched KEGG pathway of differential metabolites of tMCAO/Sham in mouse plasma.

| Pathway Name                        | p-Value | Metabolite                                                                 | Impact  |
|------------------------------------|---------|-----------------------------------------------------------------------------|---------|
| Sphingolipid metabolism            | 0.00005 | Sphingomyelin; Digalactosylceramide; Glucosylceramide; Sulfatide            | 0.07708 |
| Arachidonic acid metabolism        | 0.00568 | 5,6-EET; Phosphatidylcholine; 14,15-DHET                                     | 0.02120 |
| Linoleic acid metabolism           | 0.05207 | Phosphatidylcholine                                                         | 0.00000 |
| Glycerophospholipid metabolism     | 0.05404 | Phosphatidylethanolamine; Phosphatidylcholine                               | 0.19895 |
| Valine, leucine and isoleucine biosynthesis | 0.08208 | L-Isoleucine                                                               | 0.00000 |
| alpha-Linolenic acid metabolism    | 0.13013 | Phosphatidylcholine                                                         | 0.00000 |
| Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 0.13945 | Phosphatidylethanolamine                                                   | 0.00399 |
| Terpenoid backbone biosynthesis    | 0.17581 | Dimethylallyl diphosphate                                                  | 0.00000 |
| Biosynthesis of unsaturated fatty acids | 0.32232 | (4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid                             | 0.00000 |
| Valine, leucine and isoleucine degradation | 0.35138 | L-Isoleucine                                                               | 0.00000 |
| Steroid biosynthesis               | 0.36546 | Cholesterol ester                                                          | 0.00000 |

### Table 2. The enriched KEGG pathway of differential metabolites of Cela/tMCAO in mouse plasma.

| Pathway Name                        | p-Value | Metabolite                                                                 | Impact  |
|------------------------------------|---------|-----------------------------------------------------------------------------|---------|
| Glycerophospholipid metabolism     | 0.00180 | Phosphatidylethanolamine; Phosphatidylcholine; Phosphatidylserine           | 0.24596 |
| Linoleic acid metabolism           | 0.03000 | Phosphatidylcholine                                                         | 0.00000 |
| alpha-Linolenic acid metabolism    | 0.09125 | Phosphatidylcholine                                                         | 0.00000 |
| Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 0.09795 | Phosphatidylethanolamine                                                   | 0.00399 |
| Sphingolipid metabolism            | 0.14357 | Sulfatide                                                                  | 0.00000 |
| Arachidonic acid metabolism        | 0.23436 | Phosphatidylcholine                                                         | 0.00000 |
| Tryptophan metabolism              | 0.26262 | 5-Hydroxykynurenamine                                                      | 0.01390 |

### Table 3. The enriched KEGG pathway of differential metabolites of tMCAO/Sham in mouse brain.

| Pathway Name                        | p-Value | Metabolite                                                                 | Impact  |
|------------------------------------|---------|-----------------------------------------------------------------------------|---------|
| Sphingolipid metabolism            | 0.00200 | Sphingosine; N-Acylphosphosine; Lactosylceramide; Sulfatide                | 0.31440 |
| alpha-Linolenic acid metabolism    | 0.04800 | Phosphatidylcholine; (9Z,12Z,15Z)-Octadecatrienoic acid                    | 0.33333 |
| Linoleic acid metabolism           | 0.13204 | Phosphatidylcholine                                                         | 0.00000 |
| Glycosaminoglycan biosynthesis-chondroitin sulfate/dermatan sulfate | 0.24701 | Chondroitin                                                                | 0.00000 |
| Metabolism of xenobiotics by cytochrome P450 | 0.26300 | 2-Bromoacetalddehyde                                                       | 0.01418 |
| Arachidonic acid metabolism        | 0.26558 | S-(1,2-Dichlorovinyl)glutathione                                            | 0.07980 |
Table 3. Cont.

| Pathway Name                              | p-Value | Metabolite                                                                 | Impact  |
|-------------------------------------------|---------|---------------------------------------------------------------------------|---------|
| Glycerophospholipid metabolism            | 0.26558 | (1αααα,2ββββ,3αααα,11αααα)-1αααα,2ββββ,3αααα,11αααα-Tetrahydro-6,11-dimethylbenzo[6,7]phenanthro[3,4-b]xirene-2,3-diol | 0.19895 |
| Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 0.32816 | Phosphatidylethanolamine                                                 | 0.00399 |
| Arginine biosynthesis                      | 0.32816 | L-Arginine                                                                | 0.07614 |
| Terpenoid backbone biosynthesis            | 0.40074 | Dimethylallyl diphosphate                                                 | 0.00000 |
| Propanoate metabolism                      | 0.48077 | 2-Hydroxybutanoic acid                                                   | 0.00000 |
| Drug metabolism-cytochrome P450            | 0.53720 | Alcophosphamide                                                           | 0.00000 |
| Alanine, aspartate and glutamate metabolism | 0.55034 | N-Acetyl-L-aspartate                                                      | 0.08654 |
| Purine metabolism                          | 0.55802 | Allantoate;(S)-Ureidoglycolate                                            | 0.0012  |
| Biosynthesis of unsaturated fatty acids     | 0.64315 | (9Z,12Z,15Z)-Octadecatrienoic acid                                       | 0.00000 |
| Arginine and proline metabolism            | 0.66326 | L-Arginine                                                                | 0.05786 |
| Fatty acid degradation                      | 0.67289 | L-Palmitoylcarnitine                                                     | 0.00000 |
| Steroid biosynthesis                        | 0.70021 | Cholesterol ester                                                         | 0.00000 |
| Aminoacyl-tRNA biosynthesis                 | 0.74833 | L-Arginine                                                                | 0.00000 |
| Steroid hormone biosynthesis                | 0.89308 | Pregnenolone                                                              | 0.03776 |

Table 4. The enriched KEGG pathway of differential metabolites of Cela/tMCAO in mouse brain.

| Pathway Name                              | p-Value | Metabolite                                                                 | Impact  |
|-------------------------------------------|---------|---------------------------------------------------------------------------|---------|
| Sphingolipid metabolism                   | 0.01000 | N-Acylsphingosine; Sulfatide                                              | 0.26978 |
| Propanoate metabolism                     | 0.18199 | 2-Hydroxybutanoic acid                                                   | 0.00000 |
| Alanine, aspartate and glutamate metabolism | 0.21727 | N-Acetyl-L-aspartate                                                      | 0.08654 |
| Glycerophospholipid metabolism            | 0.27080 | 1-Acyl-sn-glycero-3-phosphocholine                                        | 0.01736 |
| Steroid biosynthesis                       | 0.30871 | Cholesterol ester                                                         | 0.00000 |
| Metabolism of xenobiotics by cytochrome P450 | 0.43269 | (1αααα,2ββββ,3αααα,11αααα)-1αααα,2ββββ,3αααα,11αααα-Tetrahydro-6,11-dimethylbenzo[6,7]phenanthro[3,4-b]xirene-2,3-diol | 0.00000 |
| Steroid hormone biosynthesis               | 0.49595 | 11-Deoxycortisol                                                         | 0.01317 |

3. Discussion
Lipids are essential for sustaining the normal structure and function of the CNS, among which fatty acids, triglycerides, phospholipids, sterol lipids, and sphingolipids are the most important categories [22]. Previous studies suggested that the curative effect of some natural medicines on ischemic stroke may be associated with its regulation of lipid metabolism such as glycerophospholipid and sphingolipid metabolism [28]. Additionally, celastrol has been clarified to have the neuroprotective effect on ischemic stroke as well as the lipid-regulating effect on diseases such as colitis [15]. Under this background, our study also found that celastrol could alleviate cerebral I/R injury in tMCAO mice, and celastrol exhibited anti-apoptosis effect in our research. Furthermore, our lipidomics results on the ischemic hemisphere and plasma of mice, revealed that the neuroprotection of celastrol may related with its effect by altering the level of sulfatide, phosphatidylcholine (PC), and phosphatidylethanolamine (PE) in sphingolipid and glycerophospholipid metabolism.
In our study, the pathway enrichment analysis showed sphingolipid and glycerophospholipid metabolism were significantly enriched ($p < 0.05$) between the Sham, tMCAO and Celastrol-treated tMCAO groups. Brain contains large proportion of lipids, particularly sphingolipids and glycerophospholipids, which have been regarded as the critical constituent of the cell membrane and participate in maintaining the normal physiological process of CNS [29–33]. Accumulating studies have identified that these two lipid metabolism disorders contributed to the pathogenesis of ischemic stroke [23,34]. Consistently, our lipidomic analysis illustrated the levels of sphingolipids and glycerophospholipids were altered in tMCAO group. Moreover, consistent with the previous studies which highlighted that celastrol was able to interfere with sphingolipid and glycerophospholipid metabolism [13], we observed the alteration of these two lipids induced by tMCAO were blocked after celastrol intervention, suggesting the underlying mechanism of celastrol in relieving cerebral I/R injury was very likely related to its regulation of sphingolipid and glycerophospholipid metabolic pathway.

Among many sphingolipids, our lipidomic analysis found sulfatide was significantly up-regulated in brain and plasma after cerebral I/R injury, which reversed by celastrol, implying that sulfatide may be a target of celastrol in treating cerebral I/R injury. Sulfatide, also known as 3-O-sulfogalactosylceramide, is abundantly present in the myelin sheath of the CNS, plays a critical role in regulating and maintaining myelin-associated physiological events [35–37]. To date, several studies have focused on the relationship between sulfatide and CNS diseases [38–40]. Sulfatide was reported to induce neuronal apoptosis and increase NF-κB, p-JNK, and p-c-Jun in brain [41]. Intriguingly, celastrol and sulfatide had the opposite effect on the same targets in brain, as celastrol was found to suppress the ischemic stroke-induced upregulation of NF-κB, p-JNK, and p-c-Jun in brain [15,17]. Since NF-κB and JNK pathways act as a key role in regulating ischemia-induced apoptosis [42,43], the relationship between celastrol, sulfatide, and apoptosis attracted our attention. Previous studies have proved that the protective effect of celastrol on ischemic stroke is related to its regulation of apoptotic responses via inhibiting NF-κB [17]. In this study, our results confirmed that celastrol was able to prevent ischemia-induced neuronal apoptosis and regulate sulfatide metabolism. Based on all the above, we hypothesize the mechanism of celastrol protects against cerebral I/R injury may be attributed to the decrease in sulfatide, which consequently inhibits sulfatide-triggered elevated expressions of NF-κB, p-JNK, and p-c-Jun, thus ultimately reduces ischemic stroke-induced cell apoptosis. However, the underlying mechanism still needs further research to explore.

As the main category of glycerophospholipids, the dysregulation of PC and PE metabolism was observed in tMCAO group, indicating that these two lipids may be involved in the pathological development of cerebral I/R injury. PC and PE are found to be deemed as the major phospholipids in cell membranes, which are responsible for protein biogenesis and activation, oxidative phosphorylation, and mitochondrial stability [33,44,45]. As we know, PC and PE can be hydrolyzed by lipoprotein-associated phospholipaseA2 (PLA2) into lysophosphatidylcholines (LPC) and lysophosphatidylethanolamine (LPE), thereby leading to the production of the second messenger arachidonic acid (AA) [27,46]. The release of AA leads to the activation of cyclooxygenase (COX) which could cause cell apoptosis [47]. In addition, it was found that PLA2 was the target of celastrol and inhibition of PLA2 could reduce the hydrolysis of PC and PE, exerting protective effects in ischemic stroke [27,48]. In our study, celastrol was able to attenuate cerebral I/R-induced PC and PE metabolism disturbance. Additionally, PLA2 may be involved in this process. Meanwhile, the anti-apoptotic effect of celastrol on cerebral ischemia was observed in our results. As apoptosis is related with phospholipid metabolism, we supposed that celastrol may regulate PC and PE metabolism by targeting PLA2, and eventually exert anti-apoptotic effect in ischemic brain, but whether our hypothesis is correct still needs experiments to explore and validate.

Taken together, lipidomics based on UPLC/MS was applied in this study to investigate the potential relationship among alteration of lipid metabolites, neuroprotective effect,
and mechanisms of celastrol on cerebral I/R injury in tMCAO mice. Our results confirmed that Celastrol-treated tMCAO mice reduced infarct volume and apoptosis-positive cells, which suggested the neuroprotection and anti-apoptosis effect of celastrol. Moreover, lipidomics analysis showed that the mechanism of celastrol in the treatment of cerebral I/R injury might partially associated with its affection on lipid metabolites in sphingolipid and glycerophospholipid metabolism pathways. Among those metabolites, sulfatide, PC, and PE may be the most important targets and the potential mechanism may relate with their anti-apoptosis effect. Although the current study provides new insights into the relationship between regulating lipid metabolism effect and the mechanism of neuroprotection when treated by celastrol, further research is still needed to elucidate the underlying mechanism of lipid metabolites-related neuroprotection in cerebral ischemic-reperfusion injury.

4. Materials and Methods

4.1. Animals

Male C57BL/6 mice (weighing 18–22 g) were purchased from the Laboratory Animal Center, Chongqing Medical University, China (License number: SYXK(Chongqing) 2018-0003). The animals were housed under sterile and controlled conditions (temperature 24 ± 2 °C, relative humidity 60 ± 10%) with a 12 h light/dark rhythm and had free access to standard food and water. All animals adapted to the environment for 5 days before experimentation. All animal experiments were carried out in accordance with the Guide for the Care and Use of Laboratory Animals and were approved by the Animal Care Committee of Chongqing Medical University. Mice were randomly divided into 3 groups: Sham group, tMCAO group, Celastrol-treated tMCAO group. Celastrol (purity 99.56%, Selleckchem, Houston, TX, USA) was dissolved in 1% dimethyl sulfoxide (dimethyl sulfoxide diluting with 0.9% saline solution) at the concentration of 4.5 mg/kg and injected intraperitoneally at the onset of reperfusion. The mice in Sham and tMCAO groups received equal volume of 1% dimethyl sulfoxide. The concentration of celastrol used in this experiment was converted from the concentration reported in previous study.

4.2. Transient Middle Cerebral Artery Occlusion (tMCAO) Model

Focal cerebral ischemia was induced using a transient middle cerebral artery occlusion (tMCAO) model according to the previous method [49,50]. In brief, mice were anesthetized with an intraperitoneal injection of 40 mg/kg sodium pentobarbital. A median incision in the neck was made to expose the right common carotid artery (CCA), external carotid artery (ECA) and internal carotid artery (ICA). A 4–0 silicon-coated nylon suture (diameter 0.21–0.25 mm, Yushun Biotech, Pingdingshan, Henan, China) was inserted from the ECA to the ICA and gently advanced forward until it obstructed the MCA. The suture was gently withdrawn 1 h after MCAO to restore blood flow for 24 h. The same surgical procedure was performed in Sham group without occluding the MCA. Body temperature was maintained between 36.5 °C to 37.5 °C throughout the experiment. To determine whether the tMCAO model was induced successfully or not, the microtip of Laser Doppler Flowmetry (Periflux System 5000, Perimed, Järfälla, Sweden) was fixed at 1 mm posterior and 5 mm lateral to the bregma to monitor the cerebral blood flow (CBF) in MCA area. A decrease in CBF ≥ 80% during the 1 h ischemic period and a recovery of CBF ≥ 70% within 10 min were considered as a successful model. After fully waking up from anesthesia, the mice were returned to their home cages.

4.3. Cerebral Infarct Volume Measurement

Cerebral ischemia/reperfusion (I/R) induced by tMCAO led to severe brain damage in experimental animals. The 2,3,5-triphenyltetrazolium chloride (TTC) staining was used to assess the cerebral infarct volume. 16 mice were randomly divided into Sham group (n = 5), tMCAO group (n = 5) and Celastrol-treated tMCAO group (n = 6). After 1 h MCAO and 24 h reperfusion, mice were anesthetized with sodium pentobarbital (40 mg/kg, I.P.) and decapitated under deep anesthesia. Immediately, brains were removed and frozen at...
−20 °C for 30 min, and then coronally cut into 5 slices at a thickness of 2 mm. The slices were incubated in a 2% TTC solution (Servicebio, Wuhan, China) and stained at 37 °C for 30 min, and subsequently fixed in 4% paraformaldehyde overnight. After TTC staining, ischemic portion appeared white and the non-ischemic portion appeared red. The infarct volume was evaluated by Image J software (National Institutes of Health, Bethesda, Maryland, MD, USA) and the following calculation formula was used: (contralateral hemisphere area−ipsilateral non-ischemic hemisphere area)/contralateral hemisphere area × 100%.

4.4. TUNEL Staining

TdT-mediated dUTP Nick-End Labeling (TUNEL) staining was performed with Colorimetric TUNEL Apoptosis Assay Kit (Beyotime Biotech, Shanghai, China) following the manufacturer’s instruction. After 24 h of reperfusion, animals in each group (3 mice per group) were anesthetized and slowly perfused with PBS and 4% paraformaldehyde for 15 min, respectively. After that, the brain was taken and fixed in 4% paraformaldehyde for 24 h. Then, the brain tissue was embedded by paraffin, and serial cut into coronal sections (5 µm-thick). To determine apoptotic cells, sections obtained 3–3.5 mm regions of the bregma from each animal were stained with TUNEL and apoptosis positive cells in the parietal cortex and hippocampal CA1 regions appeared dark brown under a light microscopy.

4.5. Sample Collection and Preparation

Ischemic hemispheres and plasma from mice in Sham (n = 6), tMCAO (n = 6) and Celastrol-treated tMCAO (n = 6) groups were selected for lipidomic analysis. Briefly, mice were sacrificed 24 h after reperfusion, and the ischemic hemisphere were collected immediately. In addition, the blood was collected in an anticoagulation tube containing EDTA and centrifuged at 1200 g at 4 °C for 10 min to obtain the plasma supernatant. The collected plasma and hemispheres were immediately placed in liquid nitrogen for 40 min and then stored at −80 °C. To extract metabolites, the plasma and ischemic hemisphere samples were thawed on ice, then 20 µL of sample was extracted with 120 µL of precooled 50% methanol, vortexed for 1 min and incubated at room temperature for 10 min, the extraction mixture was then stored overnight at −20 °C. After centrifugation at 4000 g for 20 min, the supernatants were transferred into a new 96-well plate. The samples were stored at −80 °C prior to the UPLC-MS analysis. In addition, pooled QC samples were also prepared by combining 10 µL of each extraction mixture.

4.6. Chromatography Analysis

All samples were acquired by the UPLC/MS system followed machine orders. Firstly, all chromatographic separations were performed using an ultra-performance liquid-chromatography (UPLC) system (SCIEX, Framingham, Massachusetts, MA, USA). An ACQUITY UPLC T3 column (100 mm × 2.1 mm, 1.8 µm, Waters, Milford, Massachusetts, MA, USA) was used for the reversed phase separation. The column oven was maintained at 35 °C. The flow rate was 0.4 mL/min and the mobile phase consisted of solvent A (water, 0.1% formic acid) and solvent B (acetonitrile, 0.1% formic acid). Gradient elution conditions were set as follows: 0–0.5 min, 5% B; 0.5–7 min, 5% to 100% B; 7–8 min, 100% B; 8–8.1 min, 100% to 5% B; 8.1–10 min, 5% B. The injection volume for each sample was 4 µL.

4.7. Mass Spectrometry Analysis

The eluent was introduced into the TripleTOF5600plus (SCIEX, Framingham, MA, USA) mass spectrometry (MS) to detect metabolites eluted form the column. The MS was operated using the electrospray positive-ion (ESI⁺) and negative-ion (ESI⁻) modes. The curtain gas was set at 30 PSI, Ion source gas1 was set at 60 PSI, Ion source gas2 was set at 60 PSI, and an interface heater temperature was 65 °C. For positive ion mode, the ionspray voltage floating was set at 5000 V. For negative ion mode, the ionspray voltage floating was set at −4500 V. The mass spectrometry data were acquired in IDA mode. The TOF mass range was from 60 to 1200 Da. The survey scans were acquired in 150 ms
and as many as 12 product ion scans were collected if exceeding a threshold of 100 counts per second (counts/s) and with a 1+ charge-state. Total cycle time was fixed to 0.56 s. Four-time bins were summer for each scan at a pulser frequency value of 11 kHz through monitoring of the 40 GHz multichannel TDC detector with four-anode/channel detection. Dynamic exclusion was set for 4 s. During the acquisition, the mass accuracy was calibrated every 20 samples. Furthermore, in order to evaluate the stability of the UPLC/MS during the whole acquisition, a quality control sample (pool of all samples) was acquired after every 10 samples.

4.8. Data Processing and Statistical Analysis

The data of cerebral infarct volume was presented as mean ± SEM. The statistical significance between groups were performed by one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparison test, GraphPad Prism 6.01 Software (GraphPad, San Diego, CA, USA) was used in our study. p < 0.05 was statistically significant.

The acquired MS data pretreatments including peak picking, peak grouping, retention time correction, second peak grouping, and annotation of isotopes and adducts was performed using XCMS software. UPLC/MS raw data files were converted into mzXML format and then processed by the XCMS, CAMERA and metaX toolbox implemented with the R software. Each ion was identified by combining retention time (RT) and m/z data. Intensities of each peaks were recorded and a three-dimensional matrix containing arbitrarily assigned peak indices (retention time-m/z pairs), sample names (observations) and ion intensity information (variables) was generated.

The KEGG and HMDB databases were used to annotate the metabolites by matching the exact molecular mass data (m/z) of samples with those from database. If a mass difference between observed and the database value was less than 10 ppm, the metabolite would be annotated and the molecular formula of metabolites would further be identified and validated by the isotopic distribution measurements. We also used an in-house fragment spectrum library of metabolites to validate the metabolite identification. The workflow was shown in Figure 7.

![Figure 7. Workflow of the lipidomics.](image)

The intensity of peak data was further preprocessed by metaX. Those features that were detected in less than 50% of QC samples or 80% of biological samples were removed, the remaining peaks with missing values were imputed with the k-nearest neighbor algorithm to further improve the data quality. Partial least-squares-discriminant analysis (PLS-DA) was performed for outlier detection and batch effects evaluation using the preprocessed dataset. Quality control-based robust LOESS signal correction was fitted to the QC data with respect to the order of injection to minimize signal intensity drift over
time. In addition, the relative standard deviations of the metabolic features were calculated across all QC samples, and those >30% were then removed.

Student t-tests were conducted to detect differences in metabolite concentrations between 2 phenotypes. The p value was adjusted for multiple tests using an FDR (Benjamini–Hochberg). Supervised PLS-DA was conducted through metaX to discriminate the different variables between groups. The VIP value was calculated. A VIP cut-off value of 1.0 was used to select important features.

**Supplementary Materials:** The following are available online, Table S1: Differential lipid species tMCAO/Sham in mouse plasma, according to significance evaluation and VIP values, Table S2: Table S2 Differential lipid species Cela/tMCAO in mouse plasma, according to significance evaluation and VIP values, Table S3: Differential lipid species tMCAO/Sham in mouse brain, according to significance evaluation and VIP values, Table S4: Differential lipid species Cela/tMCAO in mouse brain, according to significance evaluation and VIP values, Table S5: The enriched KEGG pathway of differential metabolites of Cela/Sham in mouse plasma, Table S6: The enriched KEGG pathway of differential metabolites of Cela/Sham in mouse brain and Table S7: Frequency of lipid metabolites and the involved KEGG pathway.

**Author Contributions:** Conceptualization, J.Y.; methodology, M.C. and M.L. (Maozhu Liu); software, M.C. and M.L. (Maozhu Liu); validation, M.C. and M.L. (Maozhu Liu); formal analysis, M.C. and M.L. (Maozhu Liu); investigation, M.C. and M.L. (Maozhu Liu); resources, M.C. and M.L. (Maozhu Liu); data curation, M.C. and M.L. (Maozhu Liu); writing—original draft preparation, M.C. and M.L. (Maozhu Liu); writing—review and editing, J.Y. and Y.L.; visualization, H.F. and H.H.; supervision, M.L. (Miaomiao Li), W.L and Z.P.; project administration, H.W.; funding acquisition, J.Y. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by Discipline Construction Fund of Central People’s Hospital of Zhanjiang (2020A01) and (2020A02).

**Institutional Review Board Statement:** The study was conducted according to the guidelines of “Chongqing Administration Rule of Laboratory Animal” and approved by the Animal Laboratory Administrative Center and the Institutional Ethics Committee of Chongqing Medical University (license number: SYXK (Chongqing) 2018-0003).

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The data presented in this study are available in Supplementary Materials.

**Acknowledgments:** This work was supported by the Discipline Construction Fund of Central People’s Hospital of Zhanjiang.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Sample Availability:** Celastrol is available from Selleck (America). Product No S1290.

References
1. Wu, S.; Wu, B.; Liu, M.; Chen, Z.; Wang, W.; Anderson, C.S.; Sandercock, P.; Wang, Y.; Huang, Y.; Cui, L.; et al. Stroke in China: Advances and challenges in epidemiology, prevention, and management. *Lancet Neurol.* 2019, 18, 394–405. [CrossRef]
2. Patel, U.K.; Dave, M.; Lekshminarayanan, A.; Malik, P.; DeMasi, M.; Chandramohan, S.; Pillai, S.; Tirupathi, R.; Shah, S.; Jani, V.B.; et al. Risk Factors and Incidence of Acute Ischemic Stroke: A Comparative Study Between Young Adults and Older Adults. *Cureus* 2021, 13, e14670. [CrossRef]
3. Tejada Meza, H.; Artal Roy, J.; Pérez Lázaro, C.; Bestué Cardiel, M.; Alberti González, O.; Tejero Juste, C.; Hernando Quintana, N.; Jarauta Lahoz, L.; Giménez Muñoz, A.; Campello Morer, I.; et al. Epidemiology and characteristics of ischaemic stroke in young adults in Aragon. *Neurologia* 2021. In Press. [CrossRef]
4. Campbell, B.C.V.; De Silva, D.A.; Macleod, M.R.; Coutts, S.B.; Schwamm, L.H.; Davis, S.M.; Donnan, G.A. Ischaemic stroke. *Nat. Rev. Dis. Primers* 2019, 5, 70. [CrossRef] [PubMed]
5. Pan, J.; Konstas, A.A.; Bateman, B.; Ortolano, G.A.; Pile-Spellman, J. Reperfusion injury following cerebral ischemia: Pathophysiology, MR imaging, and potential therapies. *Neuroradiology* 2007, 49, 93–102. [CrossRef] [PubMed]
6. Sun, K.; Fan, J.; Han, J. Ameliorating effects of traditional Chinese medicine preparation, Chinese materia medica and active compounds on ischemia/reperfusion-induced cerebral microcirculatory disturbances and neuron damage. *Acta Pharm. Sin. B* 2015, 5, 8–24. [CrossRef] [PubMed]
7. Hu, M.; Luo, Q.; Alitongbieke, G.; Chong, S.; Xu, C.; Xie, L.; Chen, X.; Zhang, D.; Zhou, Y.; Wang, Z.; et al. Celastrol-Induced Nur77 Interaction with TRAF2 Alleviates Inflammation by Promoting Mitochondrial Ubiquitination and Autophagy. *Mol. Cell* 2017, 66, 141–153. [CrossRef]

8. Shi, K.; Chen, X.; Xie, B.; Yang, S.S.; Liu, D.; Dai, G.; Chen, Q. Celastrol Alleviates Chronic Obstructive Pulmonary Disease by Inhibiting Cellular Inflammation Induced by Cigarette Smoke via the Ednrb/Kng1 Signaling Pathway. *Front. Pharmacol.* 2018, 9, 1276. [CrossRef]

9. Han, L.P.; Sun, B.; Li, C.J.; Xie, Y.; Chen, L.M. Effect of celastrol on tolllike receptor 4-mediated inflammatory response in free fatty acid-induced HepG2 cells. *Int. J. Mol. Med.* 2018, 42, 2053–2061. [CrossRef]

10. Trotta, A.; West, J.D.; Klaic, L.; Westerheide, S.D.; Silverman, R.B.; Morimoto, R.I.; Morano, K.A. Activation of heat shock and antioxidant responses by the natural product celastrol: Transcriptional signatures of a thiol-targeted molecule. *Mol. Biol. Cell* 2008, 19, 1104–1112. [CrossRef]

11. Han, X.B.; Tan, Y.; Fang, Y.Q.; Li, F. Protective effects of celastrol against gamma irradiation-induced oxidative stress in human umbilical vein endothelial cells. *Exp. Ther. Med.* 2018, 16, 685–694. [CrossRef]

12. Wang, C.; Shi, C.; Yang, X.; Yang, M.; Sun, H.; Wang, C. Celastrol suppresses obesity process via increasing antioxidant capacity and improving lipid metabolism. *Eur. J. Pharmacol.* 2014, 744, 52–58. [CrossRef] [PubMed]

13. Zhang, T.; Zhao, Q.; Xiao, X.; Yang, R.; Hu, D.; Zhu, X.; Gonzalez, F.J.; Li, F. Modulation of Lipid Metabolism by Celastrol. *J. Proteome Res.* 2019, 18, 1133–1144. [CrossRef] [PubMed]

14. Wang, R.; Gu, X.; Dai, W.; Ye, J.; Lu, F.; Chai, Y.; Fan, G.; Gonzalez, F.J.; Duan, G.; Qi, Y. A lipidomics investigation into the intervention of celastrol in experimental colitis. *Mol. Biosyst.* 2016, 12, 1436–1444. [CrossRef] [PubMed]

15. Li, Y.; He, D.; Zhang, X.; Liu, Z.; Zhang, X.; Dong, L.; Xing, Y.; Wang, C.; Qiao, H.; Zhu, C.; et al. Protective effect of celastrol in rat cerebral ischemia model: Down-regulating p-JNK, p-c-Jun and NF-kappaB. *Brain Res.* 2012, 1464, 8–13. [CrossRef] [PubMed]

16. Jiang, M.; Liu, X.; Zhang, D.; Wang, Y.; Hu, X.; Xu, F.; Jin, M.; Cao, F.; Xu, L. Celastrol treatment protects against acute ischemic stroke-induced brain injury by promoting an IL-33/ST2 axis-mediated microglia/macrophage M2 polarization. *J. Neuroinflamm.* 2018, 15, 78. [CrossRef]

17. Zhang, B.; Zhong, Q.; Chen, X.; Wu, X.; Sha, R.; Song, G.; Zhang, C.; Chen, X. Neuroprotective Effects of Celastrol on Transient Global Cerebral Ischemia Rats via Regulating HMGB1/NF-kappaB Signaling Pathway. *Front. Neurosci.* 2020, 14, 847. [CrossRef] [PubMed]

18. Zulig, T.; Trotzmuller, M.; Kofeler, H.C. Lipidomics from sample preparation to data analysis: A primer. *Anal. Bioanal. Chem.* 2020, 412, 2191–2209. [CrossRef]

19. Au, A. Metabolomics and Lipidomics of Ischemic Stroke. *Adv. Clin. Chem.* 2018, 85, 31–69. [CrossRef]

20. Ryu, W.S.; Schellingerhout, D.; Jeong, S.W.; Nahrendorf, M.; Kim, D.E. Association between Serum Lipid Profiles and Early Neurological Deterioration in Acute Ischemic Stroke. *J. Stroke Cerebrovasc. Dis.* 2020, 7, 420–438. [CrossRef]

21. Tziomalos, K.; Giampatzis, V.; Bouziana, S.D.; Spanou, M.; Kostaki, S.; Papadopoulou, M.; Angelopoulos, S.M.; Tsopozidi, M.; Savopoulos, C.; Hatzitolios, A.I. Prognostic significance of major lipids in patients with acute ischemic stroke. *Metab. Brain Dis.* 2017, 32, 395–400. [CrossRef] [PubMed]

22. Kloska, A.; Malinowska, M.; Gabig-Cimina, M.; Jakobkiewicz-Banecka, J. Lipids and Lipid Mediators Associated with the Risk and Pathology of Ischemic Stroke. *Int. J. Mol. Sci.* 2020, 21, 3618. [CrossRef]

23. Abe, T.; Niizuma, K.; Kanoke, A.; Saigusa, D.; Saito, R.; Uruno, A.; Fujimura, M.; Yamamoto, M.; Tominaga, T. Metabolomic Analysis of Mouse Brain after a Transient Middle Cerebral Artery Occlusion by Mass Spectrometry Imaging. *Neural. Med. Chir.* 2018, 58, 384–392. [CrossRef]

24. Liu, M.; Liu, X.; Wang, H.; Xiao, H.; Jing, F.; Tang, L.; Li, D.; Zhang, Y.; Wu, H.; Yang, H. Metabolomics study on the effects of Buchang Naoxintong capsules for treating cerebral ischemia in rats using UPLC-Q/TOF-MS. *J. Ethnopharmacol.* 2016, 180, 1–11. [CrossRef]

25. Duan, W.; Wang, L.; Lv, J.; Gao, K.; Lu, Y.; Qin, S.; Ma, X.; Li, J.; Ge, X. Metabolomics Study on the Effects of Salvianolic Acid B and Borneol for Treating Cerebral Ischemia in Rats by Ultra-Performance Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry. *Rejuvenation Res.* 2019, 22, 313–324. [CrossRef]

26. Liu, W.; Mu, F.; Liu, T.; Xu, H.; Chen, J.; Jia, N.; Zhang, Y.; Dou, F.; Shi, L.; Li, Y.; et al. Ultra Performance Liquid Chromatography/Quadrupole Time-of-Flight Mass Spectrometry-Based Metabonomics Reveal Protective Effect of Terminalia chebula Extract on Ischemic Stroke Rats. *Rejuvenation Res.* 2018, 21, 541–552. [CrossRef]

27. Yang, Y.; Zhong, Q.; Zhang, H.; Mo, C.; Yao, J.; Huang, T.; Zhou, T.; Tan, W. Lipidomics study of the protective effects of isosteviol sodium on stroke rats using ultra-high-performance supercritical fluid chromatography coupling with ion-trap and time-of-flight tandem mass spectrometry. *J. Pharm. Biomed. Anal.* 2018, 157, 145–155. [CrossRef]

28. Rabiei, Z.; Bigdeli, M.R.; Rasoulian, B.; Ghassempour, A.; Mirzajani, F. The neuroprotection effect of pretreatment with olive leaf extract on brain lipidomics in rat stroke model. *Phytomedicine* 2012, 19, 940–946. [CrossRef]

29. Sun, N.; Keep, R.F.; Hua, Y.; Xi, G. Critical Role of the Sphingolipid Pathway in Stroke: A Review of Current Utility and Potential Therapeutic Targets. *Transl. Stroke Res.* 2016, 7, 420–438. [CrossRef]

30. Di Pardo, A.; Maglione, V. Sphingolipid Metabolism: A New Therapeutic Opportunity for Brain Degenerative Disorders. *Front. Neurosci.* 2018, 12, 249. [CrossRef] [PubMed]
